Trial · NCT04908683
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Group 1: Ad26.RSV.preF and RSV preF Protein | 44 | Participants | ||
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Group 2: Placebo | 63 | Participants | ||
| Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI) | Group 1: Ad26.RSV.preF and RSV preF Protein | 77 | Participants | ||
| Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV-mediated Acute Respiratory Infection (ARI) | Group 2: Placebo | 101 | Participants | ||
| Number of Participants With First Occurrence of RT-PCR-Confirmed RSV Mediated LRTD During the Second Year | Group 1: Ad26.RSV.preF and RSV preF Protein | 16 | Participants | ||
| Number of Participants With First Occurrence of RT-PCR-Confirmed RSV Mediated LRTD During the Second Year | Group 2: Placebo | 29 | Participants | ||
| Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV Mediated ARI During the Second Year | Group 1: Ad26.RSV.preF and RSV preF Protein | 39 | Participants | ||
| Number of Participants With First Occurrence of Any RT-PCR-Confirmed RSV Mediated ARI During the Second Year | Group 2: Placebo | 44 | Participants | ||
| Number of Participants With First Occurrence of Predefined Clinically Relevant Disease Associated With RT-PCR-Confirmed RSV-Mediated ARI Over the Whole Study | Group 1: Ad26.RSV.preF and RSV preF Protein | 4 | Participants | ||
| Number of Participants With First Occurrence of Predefined Clinically Relevant Disease Associated With RT-PCR-Confirmed RSV-Mediated ARI Over the Whole Study | Group 2: Placebo | 11 | Participants | ||
| Number of Participants With Serious Adverse Events (SAEs) | Group 1: Ad26.RSV.preF and RSV preF Protein | 28 days post vaccination on Day 1 | 119 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) | Group 2: Placebo | 28 days post vaccination on Day 1 | 53 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) | Group 1: Ad26.RSV.preF and RSV preF Protein | First year follow-up | 446 | Participants | |
| Number of Participants With Serious Adverse Events (SAEs) | Group 2: Placebo | First year follow-up | 239 | Participants | |
| Number of Participants With Potential Adverse Events of Special Interest (AESIs) | Group 1: Ad26.RSV.preF and RSV preF Protein | 28 days post vaccination on Day 1 | 25 | Participants | |
| Number of Participants With Potential Adverse Events of Special Interest (AESIs) | Group 2: Placebo | 28 days post vaccination on Day 1 | 4 | Participants | |
| Number of Participants With Potential Adverse Events of Special Interest (AESIs) | Group 1: Ad26.RSV.preF and RSV preF Protein | First year follow-up | 71 | Participants | |
| Number of Participants With Potential Adverse Events of Special Interest (AESIs) | Group 2: Placebo | First year follow-up | 35 | Participants | |
| Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After Vaccination | Group 1: Ad26.RSV.preF and RSV preF Protein | 1076 | Participants | ||
| Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After Vaccination | Group 2: Placebo | 169 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04908683/results